Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients

Lancet Microbe. 2022 Aug;3(8):e559. doi: 10.1016/S2666-5247(22)00120-3. Epub 2022 May 27.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neutralizing
  • COVID-19 Drug Treatment*
  • Humans
  • Immunocompromised Host
  • SARS-CoV-2* / genetics

Substances

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neutralizing
  • sotrovimab

Supplementary concepts

  • SARS-CoV-2 variants